康拓医疗
(688314)
| 流通市值：23.61亿 | | | 总市值：23.61亿 |
| 流通股本：8123.92万 | | | 总股本：8123.92万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 240,117,907.83 | 153,339,916.63 | 69,917,918.34 | 275,025,921.27 |
| 营业收入 | 240,117,907.83 | 153,339,916.63 | 69,917,918.34 | 275,025,921.27 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 148,313,124.73 | 96,225,264.83 | 44,390,295.19 | 178,155,211.19 |
| 营业成本 | 47,224,844.11 | 30,521,568.88 | 13,130,989.47 | 51,752,067.44 |
| 利息支出 | 0 | - | - | - |
| 手续费及佣金支出 | 0 | - | - | - |
| 退保金 | 0 | - | - | - |
| 赔付支出净额 | 0 | - | - | - |
| 提取保险合同准备金净额 | 0 | - | - | - |
| 保单红利支出 | 0 | - | - | - |
| 分保费用 | 0 | - | - | - |
| 税金及附加 | 3,831,167.22 | 2,629,499.01 | 1,189,336.35 | 4,839,601.89 |
| 销售费用 | 44,862,221.3 | 28,840,327.28 | 13,047,392.17 | 55,056,313.4 |
| 管理费用 | 38,710,491.97 | 25,154,584.2 | 13,016,006.28 | 52,277,352.87 |
| 研发费用 | 16,399,769.03 | 10,072,523.69 | 4,655,270.57 | 17,637,641.56 |
| 财务费用 | -2,715,368.9 | -993,238.23 | -648,699.65 | -3,407,765.97 |
| 其中:利息费用 | 1,689,998.26 | 1,163,248.08 | 541,662.43 | 1,893,256.93 |
| 其中:利息收入 | 4,889,343.02 | 2,385,653.79 | 1,389,515.93 | 5,198,947.27 |
| 加:公允价值变动收益 | 0 | - | - | - |
| 加:投资收益 | -8,118,200.97 | -5,123,859.17 | -2,201,609.87 | -1,864,265.12 |
| 净敞口套期收益 | 0 | - | - | 0 |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | 395,983.5 | 395,983.5 | - | -35,376.8 |
| 资产减值损失(新) | -2,409,314.03 | -2,108,666.54 | -587,257.3 | -8,628,619.65 |
| 信用减值损失(新) | 98,342.48 | -66,487.62 | 226,872.28 | -163,968.99 |
| 其他收益 | 10,203,005.58 | 8,836,215.13 | 1,315,270.08 | 5,254,080.8 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 91,974,599.66 | 59,047,837.1 | 24,280,898.34 | 91,432,560.32 |
| 加:营业外收入 | 392,609.53 | 237,216.35 | 0.99 | 469,573.98 |
| 减:营业外支出 | 34,769.48 | 14,789.25 | - | 149,669 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 92,332,439.71 | 59,270,264.2 | 24,280,899.33 | 91,752,465.3 |
| 减:所得税费用 | 16,326,100.09 | 10,993,912.2 | 4,659,325.23 | 17,279,551.35 |
| 六、净利润 | 76,006,339.62 | 48,276,352 | 19,621,574.1 | 74,472,913.95 |
| 持续经营净利润 | 76,006,339.62 | 48,276,352 | 19,621,574.1 | 74,472,913.95 |
| 终止经营净利润 | 0 | - | - | - |
| 归属于母公司股东的净利润 | 76,713,229.82 | 48,792,223.06 | 19,935,123.47 | 75,510,975.16 |
| 少数股东损益 | -706,890.2 | -515,871.06 | -313,549.37 | -1,038,061.21 |
| (一)基本每股收益 | 0.94 | 0.6 | 0.25 | 0.93 |
| (二)稀释每股收益 | 0.94 | 0.6 | 0.25 | 0.93 |
| 八、其他综合收益 | -641,678.85 | -367,835.15 | -401,085.94 | -469,895.99 |
| 归属于母公司股东的其他综合收益 | -653,007.14 | -362,338.89 | -399,085.34 | -449,198.52 |
| 九、综合收益总额 | 75,364,660.77 | 47,908,516.85 | 19,220,488.16 | 74,003,017.96 |
| 归属于母公司股东的综合收益总额 | 76,060,222.68 | 48,429,884.17 | 19,536,038.13 | 75,061,776.64 |
| 归属于少数股东的综合收益总额 | -695,561.91 | -521,367.32 | -315,549.97 | -1,058,758.68 |
| 公告日期 | 2024-10-29 | 2024-08-14 | 2024-04-26 | 2024-04-13 |
| 审计意见(境内) | | | | 标准无保留意见 |